Piramal Pharma Ltd has completed the acquisition of an additional 40.67% stake in Yapan Bio Pvt Ltd for ₹76 crore, taking its total holding in the Hyderabad-based company to 74%.
With the completion of the transaction on August 18, Yapan Bio has become a subsidiary of Piramal Pharma. The company is a contract development and manufacturing organisation (CDMO) specialising in vaccines and biologics.
Deal strengthens biologics capabilities
The acquisition is part of Piramal Pharma’s long-term strategy to expand its presence in the biologics sector.
Yapan Bio’s advanced large-molecule capabilities will be integrated into Piramal Pharma Solutions (PPS), the company’s CDMO arm. This will enable PPS to offer broader services and support the development and scaling of complex biologic therapies.
Supports ADC development platform
Yapan Bio also supports ADCelerate, PPS’s fixed-price, integrated platform for Phase I antibody-drug conjugate (ADC) development.
The platform aims to streamline ADC development from research and development to good manufacturing practice (GMP) production in as little as 12 months.
“This strategic investment doesn’t just fuel our long-term growth; it also puts Patient Centricity into action,” said Piramal Global Pharma CEO Peter DeYoung.
“By integrating Yapan Bio’s specialised expertise into our global network, we’re empowering our partners to meet a rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need,” he said.
The acquisition is expected to strengthen Piramal Pharma’s ability to deliver complex biologics and ADCs with greater speed and consistency.